N Engl J Med·· 14 hours agoPickScore87
Sibeprenlimab in IgA Nephropathy - Final Phase 3 Trial Analysis.
In brief
In the final analysis of a phase 3 trial in IgA nephropathy, sibeprenlimab stabilized the 24-month eGFR slope and significantly reduced composite kidney end-point events.
Why it matters
24-month randomized controlled data present both eGFR slope and composite kidney end points, enabling direct comparison of sibeprenlimab versus placebo.
Source: N Engl J Med · doi.org